Risk of Tardive Dyskinesia in Older Patients: A Prospective Longitudinal Study of 266 Outpatients

Archives of General Psychiatry

Volumn 52, Issue 9, 1995, Pages 756-765

  Jeste, Dilip V ^a,b   Caligiuri, Michael P ^a,b   Paulsen, Jane S ^a,b   Heaton, Robert K ^a   Lacro, Jonathan P ^a,b   Harris, M Jackuelyn ^a,b   Bailey, Anne ^a   Fell, Robert L ^a   McAdams, Lou Ann ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; COGNITION; FEMALE; HUMAN; IATROGENIC DISEASE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; RISK FACTOR; TARDIVE DYSKINESIA;

AGE FACTORS; AGED; ALCOHOLISM; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; COMORBIDITY; CONFIDENCE INTERVALS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMAN; INCIDENCE; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MIDDLE AGE; MOVEMENT DISORDERS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS;

EID: 0029023056     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1995.03950210050010     Document Type: Article

References (64)

1. Baldessarini RJ, Cole JO, Davis JM, Gardos G, Preskorn SH, Tarsy D. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1980.
2. Kane JM, Jeste DV, Barnes TRE, Casey DE, Cole JO, Davis JM, Gualtieri CT, Schooler NR, Sprague RL, Wettstein RM. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
3. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press Ltd; 1995: 1485–1495.
4. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JMJ, Bergmann KJ, Blank K, Koblenzer J, Kahaner K. Prospective study of tardive dyskinesia incidence in the elderly. JAMA. 1991;266: 2402–2406.
5. American Psychiatric Association, Task Force on Late Neurological Effects of Antipsychotic Drugs. Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. Am J Psychiatry. 1980;137: 1163–1172.
6. Jeste DV, Wyatt RJ. Understanding and Treating Tardive Dyskinesia. New York, NY: Guilford Press Inc; 1982.
7. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18: 701–715.
8. Friedman LS, Weinrauch LS, D'Elia JA. Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med. 1987;147: 1495–1497.
9. Casey DE. Affective disorders and tardive dyskinesia. Encephale. 1988;14: 221–226.
10. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse. 1990;16: 57–66.
11. Dixon L, Weiden PJ, Haas G, Sweeney J, Frances AJ. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry. 1992;33: 121–122.
12. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics: a controlled study. Arch Gen Psychiatry. 1991;48: 259–263.
13. Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir MJ. Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150: 966–968.
14. Sewell DD, Yoshinobu BH, Caligiuri MP, Jeste DV. Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus: two case reports. Gen Hosp Psychiatry. 1992;14: 416–419.
15. Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry. 1987;22: 67–72.
16. Menza MA, Grossman N, Van Horn M, Cody R, Forman N. Smoking and movement disorders in psychiatric patients. Biol Psychiatry. 1991;30: 109–115.
17. Sramek J, Roy S, Ahrens T, Pinanong P, Cutler NR, Pi E. Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hosp Commun Psychiatry. 1991;42: 590–592.
18. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50: 723–733.
19. Paulsen JS, Heaton RK, Jeste DV. Neuropsychological impairment in tardive dyskinesia. Neuropsychology. 1994;8:2: 227–241.
20. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry. 1993;54: 327–330.
21. Muscettola G, Pampallona S, Barbato G, Casiello M, Bolini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand. 1993;87: 29–36.
22. Gardos G, Cole JO, Haskell D, Marby D, Paine SS, Moore P. The natural history of tardive dyskinesia. J Clin Psychopharmacol. 1988;8: 31S–37S.
23. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Arch Gen Psychiatry. 1988;45: 79–91.
24. Caligiuri MP, Lohr JB, Bracha HS, Jeste DV. Clinical and instrumental assessment of neuroleptic-induced parkinsonism in patients with tardive dyskinesia. Biol Psychiatry. 1991;29: 139–148.
25. Crane GE. Pseudoparkinsonism and tardive dyskinesia. Arch Neurol. 1972;27: 426–430.
26. Choulnard G, Annable L, Ross-Chouinard A, Nestoros JN. Factors related to tardive dyskinesia. Am J Psychiatry. 1979;136: 79–82.
27. Gardos G, Cole O, Haskell DS, Samson JA, Moore P, Bollng L. The course of early dyskinesia. In: American Psychiatric Association, ed. 1993 CME Syllabus and Proceedings Summary. Washington, DC: American Psychiatric Association: 1993:179. Abstract 45c.
28. Wirshing WC, Freidenberg DL, Cummlngs JL, Bartzokis G. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism. J Clin Psychopharmacol. 1989;9: 407–411.
29. Lohr JB, Caligiuri MP. Quantitative instrumental measurement of tardive dyskinesia: a review. Neuropsychopharmacology. 1992;6: 231–239.
30. Harris MJ, Panton D, Caligiuri MP, Krull AJ, Tran-Johnson TK, Jeste DV. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacol Bull. 1992;28: 87–92.
31. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull. 1993;19: 303–315.
32. Jeste DV, Lacro JP, Gilbert PL, Kline J, Kline N. Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull. 1993;19: 817–830.
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
34. Schooler N, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39: 486–487.
35. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Early Clin Drug Eval Unit Intercom. 1975;4: 3–6.
36. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12: 189–198.
37. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24: 97–99.
38. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6: 278–296.
39. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;45(suppl 212): 11–12.
40. Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology. 1979;64: 171–179.
41. Caligiuri MP, Lohr JB, Jeste DV. Instrumental evidence that age increases motor instability in neuroleptic-treated patients. J Gerontol. 1991;46:B197-B200.
42. Caligiuri MP, Lohr JB. Fine force instability: a quantitative measure of neuroleptic-induced dyskinesia in the hand. J Neuropsychiatry Clin Neurosci. 1990;2: 395–398.
43. Stein RB, Oguztoreli MN. Tremor and other oscillations in neuromuscular systems. Biol Cybern. 1976;22: 147–157.
44. Alpert M, Diamond R, Friedhoff AJ. Tremographic studies in tardive dyskinesia. Psychopharmacol Bull. 1976;12: 5–7.
45. Lohr J, Wisniewski A, Jeste DV. Neurological aspects of tardive dyskinesia. In: Nasrallah HA, Weinberger DR, eds. The Neurology of Schizophrenia. Amsterdam, the Netherlands: Elsevier Science Publishers; 1986: 97–119.
46. Caligiuri MP. Portable device for quantifying parkinsonian rigidity. Mov Disord. 1994;9: 57–63.
47. Chan HC, Manry MT, Kondraske GV. Classification of resistance to passive motion using minimum probability of error criterion. Ann Biomed Eng. 1987;15: 579–590.
48. Kischka U, Mandir AS, Ghika J, Growdon JH. Electrophysiologic detection of extrapyramidal motor signs in Alzheimer's disease. Neurology. 1993;43: 500–505.
49. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Disord. 1958;8: 669–712.
50. Cox DR. Regression models and life tables. JR Stat Soc Ser B. 1972;34: 187–220.
51. Breslow NE. A generalized Kruskal-Wallis test for comparing K samples subject to unequal pattern of censorship. Biometrika. 1970;57: 579–594.
52. Dixon WJ, Brown NB, Engleman L, Jennrich RI. BMDP Statistical Software Manual. Berkeley: University of California Press; 1990.
53. Collett D. Modelling Survival Data in Medical Research. London, England: Chapman & Hall Ltd; 1994.
54. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118: 201–210.
55. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry. 1984;141: 748–752.
56. Zito JM, Craig TJ, Wanderling J, Siegel C. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. Am J Psychiatry. 1987;144: 778–782.
57. Reardon GT, Rifkin A, Schwartz A, Myerson A, Siris SG. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry. 1989;146: 726–729.
58. Gardos G, Cole JO, LaBrie RA. Drug variables in the etiology of tardive dyskinesia. Prog Neuropsychopharmacol. 1977;1: 147–154.
59. Smith JM, Oswald WT, Kucharski T, Waterman LJ. Tardive dyskinesia: age and sex differences in hospitalized schizophrenics. Psychopharmacology. 1978;58: 207–211.
60. Lacro JP, Jeste DV. The role of ethnicity in the development of tardive dyskinesia. In: Nair NVP, Yassa R, Jeste DV, eds. Neuroleptic-Induced Movement Disorders. London, England: Cambridge University Press; 1995:.
61. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
62. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52: 173–188.
63. Jeste DV, Gilbert PL, McAdams LA, Harris MJ. Considering neuroleptic manitenance and taper on a continuum: need for individual rather than dogmatic approach. Arch Gen Psychiatry. 1995;52: 209–212.
64. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151: 825–835.